DBS analyst Mark Kong CFA has maintained their bullish stance on SNY stock, giving a Buy rating on January 31.
Mark Kong CFA has given his Buy rating due to a combination of factors related to Sanofi’s strong market position and growth potential. Sanofi is recognized as a global leader in the generic drugs industry, benefiting from its robust active pharmaceutical ingredient production capabilities. The company maintains a healthy balance sheet with strong operating cash flow, which supports its ability to invest in research and development as well as manage risks associated with patent expiries and tariffs.
Sanofi’s growth is further bolstered by the expansion of Dupixent, its blockbuster product, into new indications, including treatment for chronic obstructive pulmonary disease (COPD), which is expected to significantly drive revenue. Additionally, the prospective launches of Itepekimab and Tolebrutinib present new avenues for revenue growth, with these products targeting different patient populations. These factors, combined with a targeted price of USD64.0 based on a 14.3x forward PE, underscore the Buy rating recommendation for Sanofi’s stock.